Dr. Scott Sneddon reports

SHARP THERAPEUTICS APPOINTS CO-FOUNDER OF NATIONAL GAUCHER FOUNDATION AND CLINICAL RESEARCHER ROBIN ELY, M.D., TO ADVISORY BOARD

Sharp Therapeutics Corp. has appointed Robin Ely, MD, the clinical director and co-founder of the National Gaucher Foundation (NGF), to its advisory board.

Dr. Ely co-founded NGF in 1984 after her son was diagnosed with Gaucher disease. Dr. Ely played a pivotal role in facilitating the United States FDA (Food and Drug Administration) studies and approval of Ceredase, the first enzyme replacement therapy for Gaucher disease. Beyond her leadership at NGF, she directs the Foundation's Global Diagnostic and Treatment Initiative, bringing diagnostic capabilities and treatment access to underserved regions worldwide. Additionally, her clinical research on the management of Gaucher disease is internationally recognized. Dr. Ely earned an MD from the Georgetown University School of Medicine.

"We invited Dr. Ely to join our advisory board because her clinical experience and patient advocacy background align directly with Sharp's efforts in orphan diseases, especially Gaucher disease," said Scott Sneddon, PhD, JD, chief executive officer of Sharp Therapeutics. "Our mission is to develop medicines that restore function and meaningfully improve the lives of patients with genetic diseases. With '901 for Gaucher disease and a growing pipeline of programs in other high-need genetically defined indications, we aim to deliver transformative therapies for patients. As we prepare to initiate clinical studies later this year, Dr. Ely will bring unparalleled insights to our upcoming phase 1 study and our anticipated future registrational development activities."

Dr. Ely joins the Sharp advisory board along with other distinguished advisers, including:

• Mark Goldberg, MD, is an expert in developing and commercializing therapies for rare diseases. He has served as senior vice-president of clinical development at Genzyme where he played a central role in the development and regulatory approval of benchmark enzyme replacement therapies, including Fabrazyme for Fabry disease, Aldurazyme for MPS I, and Myozyme and Lumizyme for Pompe disease. Following Genzyme, Dr. Goldberg served as senior vice-president and then executive vice-president of global medical and regulatory strategy at Synageva BioPharma, where he played a key role in the development and approval of Kanuma (sebelipase alfa), an enzyme replacement therapy for lysosomal acid lipase deficiency (LALD), leading to the acquisition of Synageva by Alexion for $8.4-billion. He has also served on the executive team and board of multiple biopharma companies, including ImmunoGen, Glycomimetics, Blueprint Medicines, Avacta Group and Walden Biosciences. Dr. Goldberg received his BA from Harvard College and MD from Harvard Medical School.
• Blaine McKee, PhD, is president and chief executive officer of Walden Biosciences. Dr. McKee has over 25 years of experience with expertise in corporate strategy and business development. He previously served as EVP and chief business officer at ImmunoGen, where he led corporate development, alliance management, commercial assessment and valuation functions. Before ImmunoGen, Dr. McKee was head of corporate development at Shire, leading corporate strategy, M&A and licensing. At Shire, he oversaw numerous transactions bringing key therapies into the Shire portfolio. His earlier career included a 15-year tenure at Genzyme, where he rose to SVP of strategic development for transplant, oncology and multiple sclerosis, leading business development and strategic transactions across multiple therapeutic areas. Dr. McKee received his BS in chemistry from Colorado State University, his PhD in organic chemistry from MIT and his MBA in finance from the MIT Sloan School of Management.

About Sharp Therapeutics Corp.

Sharp Therapeutics is a preclinical-stage company developing first-choice small-molecule therapeutics for genetic diseases. The company's discovery platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.

We seek Safe Harbor.